Value
6.3/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 4.8 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 9.0 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 12.1x
- ▸PEG: 0.02
ANAB · Why this verdict
Why AnaptysBio (ANAB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business is materially dependent on a single pipeline asset — rosnilimab — and a single counterparty partner. This dual concentration means a clinical setback, partnership renegotiation, or regulatory delay could eliminate most of the company's near-term value in a single event. Bear case | If concentration risk crystallizes, the stock would decline more than 30% from current levels on a single negative pipeline or partner event. | →Stable |
| CounterAnalyst consensus carries roughly 46% upside to current price, implying the market currently places significant probability on a favorable outcome for that asset; if the data hold, concentration becomes a feature rather than a risk. | ||
Business quality scores below the minimum floor, with no identifiable competitive moat and a free cash flow margin of only 4% against a FCF yield of 0.5%. These metrics indicate the company is not yet generating returns that justify a buy-and-hold posture. Quality breakdown | FCF margin improves above 10% and the Piotroski F-Score remains above 6 for 2 consecutive quarters. | →Stable |
| CounterFor a clinical-stage-adjacent biotech, low FCF margin may reflect investment in pipeline advancement rather than structural weakness; a successful trial readout or partnership milestone payment could sharply improve cash generation. | ||
Over the last four quarters the company has beaten consensus estimates every time, with average positive surprise above 59% — including a 141% beat and a 69% beat in two of those periods. This degree of consistent outperformance suggests estimates are being set well below achievable outcomes. Earnings | EPS surprise remains positive for at least 2 more consecutive quarters, with the average beat staying above 10%. | →Stable |
| CounterRevenue has been declining at roughly -8% year over year, meaning earnings beats may reflect cost reductions or partnership milestones rather than durable operating leverage; if the revenue decline continues, the earnings beat streak becomes unsustainable. | ||
The stock has formed a golden cross, trades above all key moving averages, and is showing volume accumulation via rising on-balance volume. RSI at 55 and a bullish MACD signal confirm constructive near-term price action without being overbought. Momentum breakdown | Price remains above the 200-day moving average and on-balance volume continues rising over the next two quarters. | →Stable |
| CounterMomentum in small-cap biotechs can reverse sharply on a single data or regulatory event; with 24% of the float sold short, any adverse catalyst could produce a disorderly decline despite the current technical strength. | ||
The business is materially dependent on a single pipeline asset — rosnilimab — and a single counterparty partner. This dual concentration means a clinical setback, partnership renegotiation, or regulatory delay could eliminate most of the company's near-term value in a single event.
→StableBear case
- Expectation
- If concentration risk crystallizes, the stock would decline more than 30% from current levels on a single negative pipeline or partner event.
CounterAnalyst consensus carries roughly 46% upside to current price, implying the market currently places significant probability on a favorable outcome for that asset; if the data hold, concentration becomes a feature rather than a risk.
Business quality scores below the minimum floor, with no identifiable competitive moat and a free cash flow margin of only 4% against a FCF yield of 0.5%. These metrics indicate the company is not yet generating returns that justify a buy-and-hold posture.
→StableQuality breakdown
- Expectation
- FCF margin improves above 10% and the Piotroski F-Score remains above 6 for 2 consecutive quarters.
CounterFor a clinical-stage-adjacent biotech, low FCF margin may reflect investment in pipeline advancement rather than structural weakness; a successful trial readout or partnership milestone payment could sharply improve cash generation.
Over the last four quarters the company has beaten consensus estimates every time, with average positive surprise above 59% — including a 141% beat and a 69% beat in two of those periods. This degree of consistent outperformance suggests estimates are being set well below achievable outcomes.
→StableEarnings
- Expectation
- EPS surprise remains positive for at least 2 more consecutive quarters, with the average beat staying above 10%.
CounterRevenue has been declining at roughly -8% year over year, meaning earnings beats may reflect cost reductions or partnership milestones rather than durable operating leverage; if the revenue decline continues, the earnings beat streak becomes unsustainable.
The stock has formed a golden cross, trades above all key moving averages, and is showing volume accumulation via rising on-balance volume. RSI at 55 and a bullish MACD signal confirm constructive near-term price action without being overbought.
→StableMomentum breakdown
- Expectation
- Price remains above the 200-day moving average and on-balance volume continues rising over the next two quarters.
CounterMomentum in small-cap biotechs can reverse sharply on a single data or regulatory event; with 24% of the float sold short, any adverse catalyst could produce a disorderly decline despite the current technical strength.
TrendMatrix Research · core thesis
Engine thesis — one sentence
AnaptysBio has delivered four consecutive earnings beats with an average positive surprise exceeding 59%, momentum is technically constructive with a golden cross and above all moving averages, but the pipeline is concentrated in a single asset partnered with one counterparty, and quality remains below the minimum threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 4.5 |
| Gross margin | 4.9 |
| Net margin | 0.0 |
| Current ratio | 5.4 |
| FCF quality | 3.7 |
| Moat | 3.2 |
| Piotroski F | 6.7 |
- ▸FCF-positive but moderate margins (FCF margin 4%, FCF yield 0.4%)
- ▸No competitive moat
Growth
0.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.5 |
- ▸Declining revenue: -8%
Momentum
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 2.7 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 9.2 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 40%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
2.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.8 |
| quality rank | 1.8 |
| growth rank | 3.1 |
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.2 |
| support resistance | 3.6 |
| 52w position | 7.2 |
Risk (lower is worse)
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 1.5 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 36%
- ▸Elevated put/call: 10.40
- ▸High IV: 112%
- ▸Above max pain $50
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.5>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:31d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.4<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.44
Upside
+21.6%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 62, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Catalyst at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.4<1.5@spot.
The strongest dimensions are Catalyst at 7.5, Sentiment at 6.4, and Value at 6.3; the weakest are Growth at 0.5, Risk (lower is worse) at 1.8, and Peer rank at 2.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.44 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Earnings Beat Pattern
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Technical Breakout Momentum
Trip ifPrice closes below the 200-day moving average for 3 consecutive weeks.
- P3Pipeline Counterparty Concentration Risk
Trip ifA negative pipeline or partner event causes the stock to decline more than 30% from current price within any 30-day window.
- P4Quality Below Minimum Threshold
Trip ifFCF margin rises above 10% and is sustained for 2 consecutive quarters.